Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, announced on November 13, 2026, the launch of its 4RISE™ high-throughput wet-lab validation services for AI-designed protein binders. The services are designed to bridge the gap between computational protein design and experimental validation, which remains essential to determine whether AI-generated designs translate into meaningful target interactions.
The 4RISE™ platform combines rapid experimental turnaround, scalable screening workflows, and structured data delivery to support continuous design-test-learn cycles in AI-driven discovery. Central to the offering is Sino Biological’s XPressMAX™ Cell-Free Protein Synthesis (CFPS) platform, which enables recombinant protein synthesis in just three hours, with expression success rates exceeding 99% in established workflows. The platform supports the synthesis of miniproteins, VHHs, scFvs, Fabs, enzymes, and cytokines, accelerating experimental testing of AI-designed candidates.
Using Carterra high-throughput SPR, Biacore SPR, and Octet BLI, 4RISE™ delivers high-throughput binding screening, kinetic analysis, and affinity determination. Combined with CFPS, the workflow provides sequence-to-AI-ready binding data in as little as three days, with structured data accessible in real time via API for seamless downstream research and analysis. The announcement was distributed via NEWMEDIAWIRE.
The services include four rapid screening options: Rapid Hit Discovery for binding-positive miniproteins and VHHs through crude-supernatant screening; Comparative Binder Screening for purified candidates under standardized conditions; Affinity & Kinetic Characterization for quantitative binding insights; and Specialized Binder Expression & Validation for diverse binder formats. Beyond binding, 4RISE™ offers more than 20 developability assays, over 1,000 protein bioactivity assays, and more than 10 cell-based functional assays to support in-depth candidate evaluation.
Sino Biological has experience working with AI companies on wet-lab validation for AI-designed antibody discovery, de novo binder design, and computational protein engineering. The company’s 4RISE™ wet-lab validation has supported studies published in Science, Nature Communications, Scientific Reports, and other high-impact journals. “AI-designed molecules need reliable wet-lab experimental evidence to demonstrate their potential,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. “Our integrated capabilities provide the high-quality data researchers need to evaluate candidates quickly, shorten design cycles, and turn promising discoveries into real-world applications.”
The launch matters because AI-driven protein design is rapidly generating novel binder candidates, but without experimental validation, computational predictions remain uncertain. By offering fast, scalable, and data-rich validation, 4RISE™ could significantly shorten design cycles and reduce bottlenecks in drug discovery. Researchers can Explore 4RISE™ High-Throughput Wet-Lab Validation Services Now! to learn more about the platform’s capabilities. Sino Biological, which serves researchers in more than 90 countries, continues to support basic research, drug discovery, vaccine development, and diagnostics through its recombinant proteins, antibodies, and customized services. The full release is available on www.newmediawire.com.
